#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3880148	B	Inhibition of A-Raf (unknown origin) assessed as decrease in biotin-tagged MEK1 phosphorylation after 45 mins	Homo sapiens	34		single protein format	Patent Bioactivity Data
2.	ALA3880149	B	Inhibition of B-Raf (unknown origin) assessed as decrease in biotin-tagged MEK1 phosphorylation after 45 mins	Homo sapiens	90		single protein format	Patent Bioactivity Data
3.	ALA3880150	B	Inhibition of B-Raf V600E mutant (unknown origin) assessed as decrease in biotin-tagged MEK1 phosphorylation after 45 mins	Homo sapiens	91		single protein format	Patent Bioactivity Data
4.	ALA3880151	B	Inhibition of C-Raf1 (unknown origin) assessed as decrease in biotin-tagged MEK1 phosphorylation after 45 mins	Homo sapiens	70		single protein format	Patent Bioactivity Data
5.	ALA3880153	F	Cytotoxicity against human A375 cells expressing B-RAF V600E mutant assessed as growth inhibition after 3 days by ATPlite 1 step luminescence assay	Homo sapiens	90		cell-based format	Patent Bioactivity Data
6.	ALA3880154	F	Cytotoxicity against human COLO205 cells expressing B-RAF V600E mutant assessed as growth inhibition after 3 days by ATPlite 1 step luminescence assay	Homo sapiens	74		cell-based format	Patent Bioactivity Data
7.	ALA3880159	F	Cytotoxicity against human SW620 cells expressing Ras mutant assessed as growth inhibition at 10 uM after 3 days by ATPlite 1 step luminescence assay	Homo sapiens	62		cell-based format	Patent Bioactivity Data
8.	ALA3880160	F	Antitumor activity against human COLO205 cells xenografted in nu/nu mouse assessed as tumor growth inhibition at 10 mg/kg administered for 14 days measured twice a week during compound dosing relative to control	Homo sapiens	15		organism-based format	Patent Bioactivity Data
9.	ALA3880161	A	Aqueous solubility of the compound in simulated gastric fluid at pH 1.5		65		tissue-based format	Patent Bioactivity Data
10.	ALA3880162	A	Aqueous solubility of the compound in simulated intestinal fluid at pH 4.5		65		assay format	Patent Bioactivity Data
11.	ALA3880163	A	Aqueous solubility of the compound in simulated intestinal fluid at pH 6.8		65		assay format	Patent Bioactivity Data
12.	ALA3880164	P	Aqueous solubility of the compound in hepes buffer at pH 7.4		65		small-molecule physicochemical format	Patent Bioactivity Data
13.	ALA3880165	A	Inhibition of CYP1A2 (unknown origin) using CEC as substrate after 15 mins	Homo sapiens	85		single protein format	Patent Bioactivity Data
14.	ALA3880166	A	Inhibition of CYP2C19 (unknown origin) using CEC as substrate after 30 mins	Homo sapiens	84		single protein format	Patent Bioactivity Data
15.	ALA3880167	A	Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins	Homo sapiens	85		single protein format	Patent Bioactivity Data
16.	ALA3880168	A	Inhibition of CYP2D6 (unknown origin) using AMMC as substrate after 30 mins	Homo sapiens	85		single protein format	Patent Bioactivity Data
17.	ALA3880169	A	Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Homo sapiens	85		single protein format	Patent Bioactivity Data
18.	ALA3880170	A	Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Homo sapiens	85		single protein format	Patent Bioactivity Data
19.	ALA4814581	B	Binding affinity to wild type partial length human BRAF (S429 to E741 residues) expressed in mammalian expression system assessed as residual activity at 100 nM measured by Kinomescan assay relative to control	Homo sapiens	69		assay format	Scientific Literature
20.	ALA4814582	B	Binding affinity to wild type partial length human MAP4K5 (M1 to P297) expressed in Bacterial expression system assessed as residual activity at 100 nM measured by Kinomescan assay relative to control	Homo sapiens	69		assay format	Scientific Literature